Assenagon Asset Management
BSTC

Assenagon Asset Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Assenagon Asset Management’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,500
Closed -$1.03M – 1233
2019
Q1 		$1.03M Sell
16,500
-7,379
-31% -$488K 0.01% 682
2018
Q4 		$1.45M Buy
+23,879
New +$1.43M 0.02% 552

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management's BSTC Position: Q2 2019 in Review

Assenagon Asset Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2019, closing a stake of 16,500 shares — an estimated $1.03M sold.

Assenagon Asset Management first reported a position in BSTC in Q4 2018 and held it in 2 quarters. The position peaked at $1.45M in Q4 2018. 114 funds tracked by Wall St. Rank hold BSTC as of Q2 2019.

  • Assenagon Asset Management reported no remaining BioSpecifics Technologies Corp. position as of Q2 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 16,500 BioSpecifics Technologies Corp. shares in Q2 2019, an estimated $1.03M.
  • Assenagon Asset Management first reported a position in BioSpecifics Technologies Corp. in Q4 2018 and held it in 2 quarters.
  • Assenagon Asset Management's BioSpecifics Technologies Corp. position peaked at $1.45M in Q4 2018.
  • 114 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2019.

Based on Assenagon Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.